Cue Biopharma (Cue Biopharma) Additional Paid-In Capital : $338.23 Mil(As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Additional Paid-In Capital?

Cue Biopharma's quarterly additional paid-in capital increased from Jun. 2023 ($322.72 Mil) to Sep. 2023 ($330.38 Mil) and increased from Sep. 2023 ($330.38 Mil) to Dec. 2023 ($338.23 Mil).

Cue Biopharma's annual additional paid-in capital increased from Dec. 2021 ($262.91 Mil) to Dec. 2022 ($316.19 Mil) and increased from Dec. 2022 ($316.19 Mil) to Dec. 2023 ($338.23 Mil).

Cue Biopharma Additional Paid-In Capital Historical Data

The historical data trend for Cue Biopharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Additional Paid-In Capital Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

163.07

232.16

262.91

316.19

338.23

Cue Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															316.19	318.58	322.72	330.38	338.23

Cue Biopharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cue Biopharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cue Biopharma (Cue Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

1UC:Germany 1UC:Germany

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Executives

Anish Suri	officer: President and CSO	40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri	director, officer: CEO	40 GUEST STREET, BOSTON MA 02135
Pamela Garzone	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti	officer: Chief Medical Officer	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn	officer: Chief Business Officer	C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar	officer: CFO	40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta	officer: Chief Medical Officer	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin	officer: SVP, General Counsel and Sec	40 GUEST STREET, BOSTON MA 02135
Tamar D Howson	director
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll	director